Belgian molecular diagnostics firm Biocartis Group has built a new research and development (R&D) centre in the US as part of its strategy to advance the expansion of tests on its Idylla platform.

For the test expansion, Biocartis intends to form Companion Diagnostics (CDx) and assay content alliances. The firm has opened the facility following the transfer of R&D personnel and Idylla-related assay development assets and tests from Janssen Pharmaceuticals.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The ten assay development experts joining from Janssen are said to be part of the same team that had developed the Idylla Respiratory (IFV-RSV) Panel cleared by the US Food and Drug Administration in the third quarter of last year.

Biocartis CEO Herman Verrelst, said: “This will help us scale our R&D organisation towards the future. Also, the close proximity to many of our pharmaceutical and test content partners in the US will facilitate an efficient execution of existing and new partnerships.

“The firm has opened the facility following the transfer of R&D personnel and Idylla-related assay development assets and tests from Janssen Pharmaceuticals.”

“The Janssen team has demonstrated to have excellent assay development capabilities on our Idylla platform.

“In addition, another important advantage is that we now have access to a US pool of R&D talent that we can also tap into for future recruitment needs in light of the business growth that we aim to realise.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Under the agreement, Biocartis will work as a tenant on the planned assay development activities in the team’s current laboratory and office facilities in Raritan, New Jersey, US.

The firm’s division Biocartis US will also sign a two-year transitional lease for laboratory and office space from Janssen, and will gain laboratory equipment and ownership of the Idylla Respiratory (IFV-RSV) Panel.

This panel along with its regulatory authorisations will be transferred to the parent organisation.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact